Business Description
Syncom Formulation (India) Ltd
ISIN : INE312C01025
Compare
Compare
Traded in other countries / regions
524470.India IPO Date
2022-11-18Description
Syncom Formulation (India) Ltd is in the business of pharmaceuticals. The company operates through three segments including manufacturing and dealings in Pharmaceutical drugs and formulations, Trading of commodities, and Renting of property. It manufactures and markets pharmaceutical formulation products in various dosage forms like tablets, capsules, liquids orals, liquids vials, ampoule injections and dry vial injections, dry syrups, ointments, inhalers, and Herbals. The company's product includes generic, antiviral, antidepressant, cough suppressant, electrolyte, histamine, estrogen, and much more. It generates maximum revenue through the Pharmaceutical drugs and formulations segment.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 1.81 | |||||
| Equity-to-Asset | 0.71 | |||||
| Debt-to-Equity | 0.25 | |||||
| Debt-to-EBITDA | 1.56 | |||||
| Interest Coverage | 7.99 | |||||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | 12.47 | |||||
| Beneish M-Score | -2.03 | |||||
| WACC vs ROIC | ||||||
Growth Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -2.3 | |||||
| 3-Year EBITDA Growth Rate | -6.2 | |||||
| 3-Year EPS without NRI Growth Rate | -9.9 | |||||
| 3-Year FCF Growth Rate | -37.3 | |||||
| 3-Year Book Growth Rate | 8.9 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 26.71 | |||||
| 9-Day RSI | 37.83 | |||||
| 14-Day RSI | 45.21 | |||||
| 6-1 Month Momentum % | 55.32 | |||||
| 12-1 Month Momentum % | 130.83 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.58 | |||||
| Quick Ratio | 2.38 | |||||
| Cash Ratio | 1.23 | |||||
| Days Inventory | 41.29 | |||||
| Days Sales Outstanding | 115.74 | |||||
| Days Payable | 47.34 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -6 | |||||
| Shareholder Yield % | 0.64 |
Profitability Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 35.82 | |||||
| Operating Margin % | 10.1 | |||||
| Net Margin % | 9.96 | |||||
| FCF Margin % | -4.92 | |||||
| ROE % | 10.52 | |||||
| ROA % | 7.22 | |||||
| ROIC % | 7.67 | |||||
| 3-Year ROIIC % | -10.39 | |||||
| ROC (Joel Greenblatt) % | 26.32 | |||||
| ROCE % | 14.8 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 60.75 | |||||
| PE Ratio without NRI | 61.78 | |||||
| Shiller PE Ratio | 85.63 | |||||
| PEG Ratio | 4.54 | |||||
| PS Ratio | 6.01 | |||||
| PB Ratio | 7.12 | |||||
| Price-to-Tangible-Book | 6.82 | |||||
| EV-to-EBIT | 45.75 | |||||
| EV-to-EBITDA | 40.91 | |||||
| EV-to-Revenue | 6.64 | |||||
| EV-to-FCF | -141.27 | |||||
| Price-to-Projected-FCF | 10.23 | |||||
| Price-to-Median-PS-Value | 4.24 | |||||
| Price-to-Peter-Lynch-Fair-Value | 5.31 | |||||
| Price-to-Graham-Number | 4.49 | |||||
| Price-to-Net-Current-Asset-Value | 12.42 | |||||
| Price-to-Net-Cash | 130.38 | |||||
| Earnings Yield (Greenblatt) % | 2.19 | |||||
| FCF Yield % | -0.72 | |||||
| Forward Rate of Return (Yacktman) % | 13.44 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Syncom Formulation (India) Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ₹) | 2,866.636 | ||
| EPS (TTM) (₹) | 0.359 | ||
| Beta | 0 | ||
| Volatility % | 68.14 | ||
| 14-Day RSI | 45.21 | ||
| 14-Day ATR (₹) | 1.37361 | ||
| 20-Day SMA (₹) | 23.178 | ||
| 12-1 Month Momentum % | 130.83 | ||
| 52-Week Range (₹) | 7.25 - 27.9 | ||
| Shares Outstanding (Mil) | 940 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Syncom Formulation (India) Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Syncom Formulation (India) Ltd Stock Events
| Event | Date | Price(₹) | ||
|---|---|---|---|---|
| No Event Data | ||||
Syncom Formulation (India) Ltd Frequently Asked Questions
What is Syncom Formulation (India) Ltd(NSE:SYNCOMF)'s stock price today?
The current price of NSE:SYNCOMF is ₹20.86. The 52 week high of NSE:SYNCOMF is ₹27.90 and 52 week low is ₹7.25.
When is next earnings date of Syncom Formulation (India) Ltd(NSE:SYNCOMF)?
The next earnings date of Syncom Formulation (India) Ltd(NSE:SYNCOMF) is .
Does Syncom Formulation (India) Ltd(NSE:SYNCOMF) pay dividends? If so, how much?
Syncom Formulation (India) Ltd(NSE:SYNCOMF) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers